Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent Infection With SARS-CoV-2: Insights From a Large Healthcare Database Analysis

Gendelman et al., Autoimmunity Reviews, 19:7, July 2020, doi:10.1016/j.autrev.2020.102566
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 8% Improvement Relative Risk HCQ for COVID-19  Gendelman et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 14,520 patients in Israel Study underpowered to detect differences c19hcq.org Gendelman et al., Autoimmunity Reviews.., May 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Very small study of rheumatic disease/autoimmune disorder patients showing no significant difference but with only 3 chronic HCQ patient cases. Only considers people tested at a time when primarily symptomatic cases were tested.
Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.0011, which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
Adjusting for the difference in baseline risk using the result in Ferri et al. shows substantial benefit for HCQ, RR 0.211, but with only 3 HCQ cases the result is inconclusive. More recent studies with rheumatic disease/autoimmune condition patients provide higher confidence.
This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of case, 8.1% lower, RR 0.92, p = 0.88, treatment 3 of 36 (8.3%), control 1,314 of 14,484 (9.1%), NNT 135.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gendelman et al., 5 May 2020, retrospective, database analysis, Israel, peer-reviewed, 5 authors.
This PaperHCQAll
Contents lists available at ScienceDirect Autoimmunity Reviews
Omer Gendelman, Howard Amital, Nicola Luigi Bragazzi, Abdulla Watad, Gabriel Chodick, A B S T R A C T
Background: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. Methods: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/ colchicine therapy. Results: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). Conclusion: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
References
Appel, Kaidar-Person, Lawrence, Ben-Ayun, Katzman et al., The coronavirus pandemic in Israel: implications for radiation oncology departments, IMAJ
Covid, Team, Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12, MMWR Morb Mortal Wkly Rep
Deftereos, Siasos, Giannopoulos, Vrachatis, Angelidis et al., The GReek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol, doi:10.1016/j.hjc.2020.03.002
Dyer, Covid-19: black people and other minorities are hardest hit in US, BMJ, doi:10.1136/bmj.m1483
Garg, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 states, march, MMWR Morb Mortal Wkly Rep
Grossman, Farberov, Feld, Livneh, Ben-Zvi, Efficacy and safety of longterm treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine, Rheumatol Int
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Infantino, Damiani, Gobbi, Grossi, Lari et al., Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives, IMAJ
Jordan, Adab, Cheng, Covid-19: risk factors for severe disease and death, BMJ, doi:10.1136/bmj.m1198
Kanduc, Shoenfeld, On the molecular determinants the SARS-CoV-2 attack, Clin Immunol
Kerpel, Nissan, Klug, Amit, Konen et al., Imaging findings in four COVID-19 patients, IMAJ
Kimball, Hatfield, Arons, James, Taylor et al., Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States
Lancet, The gendered dimensions of COVID-19, Lancet
Leung, Hui, Kraus, Colchicine -update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum
Li, Yang, Zhao, Zhi, Wang et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol, doi:10.1007/s00392-020-01626-9
Livingston, Bucher, Coronavirus disease 2019 (COVID-19) in Italy, JAMA, doi:10.1001/jama.2020.4344
Oestergaard, Schmiegelow, Bruun, Skov, Petersen et al., The associations between socioeconomic status and risk of Staphylococcus aureus bacteremia and subsequent endocarditis -a Danish nationwide cohort study, BMC Infect Dis
Pascart, Richette, Colchicine in gout: an update, Curr Pharm Des
Petrilli, Jones, Yang, Rajagopalan, Donnell et al., Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in
Rodriguez-Morales, Cardona-Ospina, Gutiérrez-Ocampo, Villamizar-Peña, Holguin-Rivera et al., Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Med Infect Dis
Rubin, Baden, Morrissey SAudio Interview: Loosening Covid-19 Restrictions, N Engl J Med
Ruiz-Irastorza, Olivares, Ruiz-Arruza, Martinez-Berriotxoa, Egurbide et al., Predictors of major infections in systemic lupus erythematosus, Arthritis Res Ther
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA, doi:10.1001/jama.2020.6019
Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis
Shoenfeld, Corona, COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning, Autoimmun Rev, doi:10.1016/j.autrev.2020.102538
Sun, He, Wang, Lai, Ji et al., COVID-19: epidemiology, evolution, and cross-disciplinary perspectives, Trends Mol Med
Surveillances, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, China CDC Weekly
Tang, Godfrey, Stawell, Nikpour, Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects, Intern Med J
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.017
{ 'indexed': {'date-parts': [[2024, 3, 22]], 'date-time': '2024-03-22T22:01:33Z', 'timestamp': 1711144893980}, 'reference-count': 34, 'publisher': 'Elsevier BV', 'issue': '7', 'license': [ { 'start': { 'date-parts': [[2020, 7, 1]], 'date-time': '2020-07-01T00:00:00Z', 'timestamp': 1593561600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/501100000024', 'name': 'Canadian Institute of Health Research', 'doi-asserted-by': 'crossref'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 7]]}, 'DOI': '10.1016/j.autrev.2020.102566', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 5]], 'date-time': '2020-05-05T02:32:49Z', 'timestamp': 1588645969000}, 'page': '102566', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 66, 'title': 'Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: ' 'Insights from a large healthcare database analysis', 'prefix': '10.1016', 'volume': '19', 'author': [ {'given': 'Omer', 'family': 'Gendelman', 'sequence': 'first', 'affiliation': []}, {'given': 'Howard', 'family': 'Amital', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicola Luigi', 'family': 'Bragazzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdulla', 'family': 'Watad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriel', 'family': 'Chodick', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.autrev.2020.102566_bb0005', 'series-title': 'Pneumonia of unknown cause–C... - Google Scholar', 'author': 'World Health Organization', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0010', 'first-page': '211', 'article-title': 'The coronavirus pandemic in Israel: implications for radiation oncology ' 'departments', 'volume': '22', 'author': 'Appel', 'year': '2020', 'journal-title': 'IMAJ'}, { 'key': '10.1016/j.autrev.2020.102566_bb0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and important lessons from the coronavirus disease ' '2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases ' 'from the Chinese Center for Disease Control and Prevention', 'author': 'Wu', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.autrev.2020.102566_bb0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical characteristics of coronavirus disease 2019 in China', 'author': 'Guan', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.autrev.2020.102566_bb0025', 'doi-asserted-by': 'crossref', 'first-page': '101623', 'DOI': '10.1016/j.tmaid.2020.101623', 'article-title': 'Clinical, laboratory and imaging features of COVID-19: A systematic ' 'review and meta-analysis', 'author': 'Rodriguez-Morales', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'issue': '5', 'key': '10.1016/j.autrev.2020.102566_bb0030', 'doi-asserted-by': 'crossref', 'first-page': '483', 'DOI': '10.1016/j.molmed.2020.02.008', 'article-title': 'COVID-19: epidemiology, evolution, and cross-disciplinary perspectives', 'volume': '26', 'author': 'Sun', 'year': '2020', 'journal-title': 'Trends Mol Med'}, { 'key': '10.1016/j.autrev.2020.102566_bb0035', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijid.2020.03.017', 'article-title': 'Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) ' 'infection: a systematic review and meta-analysis', 'author': 'Yang', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.autrev.2020.102566_bb0040', 'series-title': 'China CDC Weekly', 'first-page': '113', 'article-title': 'The epidemiological characteristics of an outbreak of 2019 novel ' 'coronavirus diseases (COVID-19)—China, 2020', 'volume': '2', 'author': 'Surveillances', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0045', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s00392-020-01626-9', 'article-title': 'Prevalence and impact of cardiovascular metabolic diseases on COVID-19 ' 'in China', 'author': 'Li', 'year': '2020', 'journal-title': 'Clin Res Cardiol'}, { 'key': '10.1016/j.autrev.2020.102566_bb0050', 'doi-asserted-by': 'crossref', 'first-page': '1335', 'DOI': '10.1001/jama.2020.4344', 'article-title': 'Coronavirus disease 2019 (COVID-19) in Italy', 'volume': '323', 'author': 'Livingston', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.autrev.2020.102566_bb0055', 'article-title': 'Factors associated with hospitalization and critical illness among ' '4,103 patients with COVID-19 disease in New York City', 'author': 'Petrilli', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.autrev.2020.102566_bb0060', 'doi-asserted-by': 'crossref', 'first-page': '343', 'DOI': '10.15585/mmwr.mm6912e2', 'article-title': 'Severe outcomes among patients with coronavirus disease 2019 ' '(COVID-19)—United States, February 12–march 16, 2020', 'volume': '69', 'author': 'COVID', 'year': '2020', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'key': '10.1016/j.autrev.2020.102566_bb0065', 'series-title': 'Preliminary estimates of the prevalence of selected underlying health ' 'conditions among patients with coronavirus disease 2019—United States, ' 'February 12–march 28, 2020', 'author': 'Kimball', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0070', 'article-title': 'Covid-19: risk factors for severe disease and death', 'volume': '368', 'author': 'Jordan', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.autrev.2020.102566_bb0075', 'doi-asserted-by': 'crossref', 'first-page': '1168', 'DOI': '10.1016/S0140-6736(20)30823-0', 'article-title': 'The gendered dimensions of COVID-19', 'volume': '395', 'author': 'Lancet', 'year': '2020', 'journal-title': 'Lancet (London, England)'}, { 'key': '10.1016/j.autrev.2020.102566_bb0080', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.autrev.2020.102538', 'article-title': 'Corona (COVID-19) time musings: our involvement in COVID-19 ' 'pathogenesis, diagnosis, treatment and vaccine planning', 'author': 'Shoenfeld', 'year': '2020', 'journal-title': 'Autoimmun Rev'}, { 'key': '10.1016/j.autrev.2020.102566_bb0085', 'series-title': 'Coronavirus_med_guidelines.pdf', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0090', 'doi-asserted-by': 'crossref', 'DOI': '10.15585/mmwr.mm6915e3', 'article-title': 'Hospitalization rates and characteristics of patients hospitalized with ' 'laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, ' 'march 1–30, 2020', 'volume': '69', 'author': 'Garg', 'year': '2020', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'key': '10.1016/j.autrev.2020.102566_bb0100', 'doi-asserted-by': 'crossref', 'first-page': '589', 'DOI': '10.1186/s12879-017-2691-3', 'article-title': 'The associations between socioeconomic status and risk of ' 'Staphylococcus aureus bacteremia and subsequent endocarditis – a Danish ' 'nationwide cohort study', 'volume': '17', 'author': 'Oestergaard', 'year': '2017', 'journal-title': 'BMC Infect Dis'}, { 'key': '10.1016/j.autrev.2020.102566_bb0105', 'series-title': 'Socioeconomic gradient in health and the COVID-19 outbreak', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0110', 'article-title': 'Covid-19: black people and other minorities are hardest hit in US', 'volume': '369', 'author': 'Dyer', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.autrev.2020.102566_bb0115', 'doi-asserted-by': 'crossref', 'first-page': '67', 'DOI': '10.1016/S1473-3099(06)70361-9', 'article-title': 'New insights into the antiviral effects of chloroquine', 'volume': '6', 'author': 'Savarino', 'year': '2006', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.autrev.2020.102566_bb0120', 'doi-asserted-by': 'crossref', 'first-page': 'R109', 'DOI': '10.1186/ar2764', 'article-title': 'Predictors of major infections in systemic lupus erythematosus', 'volume': '11', 'author': 'Ruiz-Irastorza', 'year': '2009', 'journal-title': 'Arthritis Res Ther'}, { 'key': '10.1016/j.autrev.2020.102566_bb0125', 'doi-asserted-by': 'crossref', 'first-page': 'e67', 'DOI': '10.1056/NEJMe2014793', 'article-title': 'Morrissey SAudio Interview: Loosening Covid-19 Restrictions', 'volume': '382', 'author': 'Rubin', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.autrev.2020.102566_bb0130', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.6019', 'article-title': 'Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a ' 'review', 'author': 'Sanders', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.autrev.2020.102566_bb0135', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.hjc.2020.03.002', 'article-title': 'The GReek study in the effects of colchicine in COvid-19 complications ' 'prevention (GRECCO-19 study): rationale and study design', 'author': 'Deftereos', 'year': '2020', 'journal-title': 'Hellenic J Cardiol'}, { 'key': '10.1016/j.autrev.2020.102566_bb0140', 'first-page': '215', 'article-title': 'On the molecular determinants the SARS-CoV-2 attack', 'volume': '18', 'author': 'Kanduc', 'year': '2020', 'journal-title': 'Clin Immunol (Orlando, Fla)'}, { 'key': '10.1016/j.autrev.2020.102566_bb0145', 'first-page': '214', 'article-title': 'Imaging findings in four COVID-19 patients', 'volume': '22', 'author': 'Kerpel', 'year': '2020', 'journal-title': 'IMAJ'}, { 'key': '10.1016/j.autrev.2020.102566_bb0150', 'first-page': '203', 'article-title': 'Serological assays for SARS-CoV-2 infectious disease: benefits, ' 'limitations and perspectives', 'volume': '22', 'author': 'Infantino', 'year': '2020', 'journal-title': 'IMAJ'}, { 'key': '10.1016/j.autrev.2020.102566_bb0155', 'doi-asserted-by': 'crossref', 'first-page': '341', 'DOI': '10.1016/j.semarthrit.2015.06.013', 'article-title': 'Colchicine --- update on mechanisms of action and therapeutic uses', 'volume': '45', 'author': 'Leung', 'year': '2015', 'journal-title': 'Semin Arthritis Rheum'}, { 'key': '10.1016/j.autrev.2020.102566_bb0165', 'series-title': 'Colchicine coronavirus SARS-CoV2 trial (COLCORONA) - full text view - ' 'ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04322682', 'year': '2020'}, { 'key': '10.1016/j.autrev.2020.102566_bb0170', 'doi-asserted-by': 'crossref', 'first-page': '968', 'DOI': '10.1111/j.1445-5994.2012.02886.x', 'article-title': 'Hydroxychloroquine in lupus: emerging evidence supporting multiple ' 'beneficial effects', 'volume': '42', 'author': 'Tang', 'year': '2012', 'journal-title': 'Intern Med J'}, { 'key': '10.1016/j.autrev.2020.102566_bb0175', 'doi-asserted-by': 'crossref', 'first-page': '684', 'DOI': '10.2174/1381612824999180115103951', 'article-title': 'Colchicine in gout: an update', 'volume': '24', 'author': 'Pascart', 'year': '2018', 'journal-title': 'Curr Pharm Des'}, { 'key': '10.1016/j.autrev.2020.102566_bb0180', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1007/s00296-018-04237-w', 'article-title': 'Efficacy and safety of long-term treatment with intravenous colchicine ' 'for familial Mediterranean fever (FMF) refractory to oral colchicine', 'volume': '39', 'author': 'Grossman', 'year': '2019', 'journal-title': 'Rheumatol Int'}], 'container-title': 'Autoimmunity Reviews', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1568997220301282?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1568997220301282?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 6, 1]], 'date-time': '2020-06-01T21:12:40Z', 'timestamp': 1591045960000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1568997220301282'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7]]}, 'references-count': 34, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2020, 7]]}}, 'alternative-id': ['S1568997220301282'], 'URL': 'http://dx.doi.org/10.1016/j.autrev.2020.102566', 'relation': {}, 'ISSN': ['1568-9972'], 'subject': ['Immunology', 'Immunology and Allergy'], 'container-title-short': 'Autoimmunity Reviews', 'published': {'date-parts': [[2020, 7]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Continuous hydroxychloroquine or colchicine therapy does not prevent infection ' 'with SARS-CoV-2: Insights from a large healthcare database analysis', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Autoimmunity Reviews', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.autrev.2020.102566', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier B.V. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '102566'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit